


Patients with moderate-severe MDD HAMD-17≥22 and MADRS≥32
1:1:1 Randomized, Double-Blind
Placebo (PBO)
Compound (1) 20 mg
Compound (1) 30 mg
14-Day Treatment
Controlled Follow-Up
Day 15 Primary Endpoint
Day 42 Follow-up
6-Month Post Naturalistic Follow-up

FIG. 1



CFB=change from baseline; MMRM=mixed model for repeated measure; SE=standard error; p=NS for all timepoints PBO vs Compound (1).

FIG. 2



PBO
Compound (1) 30 mg
Women
Men
% of Patients
100
80
60
40
20
0
80.0
90.1
68.1
72.1
71.0
76.0
68.1
71.0
80.4
71.1
63.3
54.8
61.2
58.5
61.4
56.8
Baseline
Day 15
Day 28
Day 42

FIG. 3



CSFQ-14 SUBSCALE ODDS RISK WITH 95% CI
GEE RESULTS WOMEN
Odds Ratio
(Compound (1) vs Placebo)
0
1
2
3
4
5
6
P value
Day 15 0.0454
Day 28 0.6478
Day 42 0.7243
Day 15 0.8217
Day 28 0.5853
Day 42 0.6462
Day 15 0.2310
Day 28 0.2324
Day 42 0.4564
Day 15 0.9902
Day 28 0.0324
Day 42 0.5541
Day 15 0.6089
Day 28 0.2530
Day 42 0.6884
Desire/Frequency
Desire/Interest
Arousal/Excitement
Orgasm/Completion
Pleasure
GEE=generalized estimating equation.

FIG. 4



CSFQ-14 SUBSCALE ODDS RISK WITH 95% CI
GEE RESULTS MEN
Odds Ratio
(Compound (1) vs Placebo)
0
1
2
3
4
5
6
P value
Day 15 0.9935
Day 28 0.7666
Day 42 0.1374
Desire/Frequency
Day 15 0.3492
Day 28 0.9890
Day 42 0.2840
Desire/Interest
Day 15 0.8647
Day 28 0.3265
Day 42 0.0384
Arousal/Excitement
Day 15 0.1327
Day 28 0.3846
Day 42 0.6845
Orgasm/Completion
Day 15 0.4608
Day 28 0.2722
Day 42 0.5211
Pleasure
GEE=generalized estimating equation.

FIG. 5